Literature DB >> 21798378

Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.

Madhavi A Jadhav1, R Cory Lucas, Whitney N Goldsberry, Muriel C Maurer.   

Abstract

Thrombin helps to activate Factor XIII (FXIII) by hydrolyzing the R37-G38 peptide bond. The resultant transglutaminase introduces cross-links into the fibrin clot. With the development of therapeutic coagulation factors, there is a need to better understand interactions involving FXIII. Such knowledge will help predict ability to activate FXIII and thus ability to promote/hinder the generation of transglutaminase activity. Kinetic parameters have been determined for a series of thrombin species hydrolyzing the FXIII (28-41) V34X activation peptides (V34, V34L, V34F, and V34P). The V34P substitution introduces PAR4 character into the FXIII, and the V34F exhibits important similarities to the cardioprotective V34L. FXIII activation peptides containing V34, V34L, or V34P could each be accommodated by alanine mutants of thrombin lacking either the W60d or Y60a residue in the 60-insertion loop. By contrast, FXIII V34F AP could be cleaved by thrombin W60dA but not by Y60aA. FXIII V34P is highly reliant on the thrombin W215 platform for its strong substrate properties whereas FXIII V34F AP becomes the first segment that can maintain its K(m) upon loss of the critical thrombin W215 residue. Interestingly, FXIII V34F AP could also be readily accommodated by thrombin L99A and E217A. Hydrolysis of FXIII V34F AP by thrombin W217A/E217A (WE) was similar to that of FXIII V34L AP whereas WE could not effectively cleave FXIII V34P AP. FXIII V34F and V34P AP show promise for designing FXIII activation systems that are either tolerant of or greatly hindered by the presence of anticoagulant thrombins.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21798378      PMCID: PMC3645320          DOI: 10.1016/j.bbapap.2011.07.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  60 in total

1.  Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males.

Authors:  U Wartiovaara; M Perola; H Mikkola; K Tötterman; V Savolainen; A Penttilä; P J Grant; M J Tikkanen; E Vartiainen; P J Karhunen; L Peltonen; A Palotie
Journal:  Atherosclerosis       Date:  1999-02       Impact factor: 5.162

Review 2.  Protease-activated receptors in hemostasis, thrombosis and vascular biology.

Authors:  S R Coughlin
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

3.  Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.

Authors:  T A Trumbo; M C Maurer
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

Review 4.  Fibrinogen and fibrin.

Authors:  John W Weisel
Journal:  Adv Protein Chem       Date:  2005

5.  Hirudin binding reveals key determinants of thrombin allostery.

Authors:  Kristen E Mengwasser; Leslie A Bush; Peter Shih; Angelene M Cantwell; Enrico Di Cera
Journal:  J Biol Chem       Date:  2005-05-27       Impact factor: 5.157

6.  Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C.

Authors:  D Arosio; Y M Ayala; E Di Cera
Journal:  Biochemistry       Date:  2000-07-11       Impact factor: 3.162

7.  The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.

Authors:  R A Ariëns; H Philippou; C Nagaswami; J W Weisel; D A Lane; P J Grant
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C.

Authors:  Hong Xu; Leslie A Bush; Agustin O Pineda; Sonia Caccia; Enrico Di Cera
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

9.  The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.

Authors:  Matthew J Flick; Anil K Chauhan; Malinda Frederick; Kathryn E Talmage; Keith W Kombrinck; Whitney Miller; Eric S Mullins; Joseph S Palumbo; Xunzhen Zheng; Naomi L Esmon; Charles T Esmon; Sherry Thornton; Ann Becker; Leslie A Pelc; Enrico Di Cera; Denisa D Wagner; Jay L Degen
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

Review 10.  Directing thrombin.

Authors:  David A Lane; Helen Philippou; James A Huntington
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

View more
  2 in total

1.  Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.

Authors:  Madhavi A Jadhav; Whitney N Goldsberry; Sara E Zink; Kelsey N Lamb; Katelyn E Simmons; Carmela M Riposo; Boris A Anokhin; Muriel C Maurer
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-07-04       Impact factor: 3.036

2.  Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation.

Authors:  Katharina Hess; Ramzi Ajjan; Fladia Phoenix; József Dobó; Péter Gál; Verena Schroeder
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.